Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Farago

Showing results (51-60 of 63) with videos related to

Pageof 7
Sort By:
JCO Precision Oncology|January 30, 2018
Tracking the Evolution of Resistance to ALK Tyrosine Kinase Inhibitors through Longitudinal Analysis of Circulating Tumor DNAIbiayi Dagogo-Jack, A Rose Brannon, Lorin A Ferris, et al.
The Lancet. Oncology|February 28, 2020
Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trialsDavid S Hong, Steven G DuBois, Shivaani Kummar, et al.
Cancer Discovery|September 27, 2018
Exploiting MCL1 Dependency with Combination MEK + MCL1 Inhibitors Leads to Induction of Apoptosis and Tumor Regression in <i>KRAS</i>-Mutant Non-Small Cell Lung CancerVaruna Nangia, Faria M Siddiqui, Sean Caenepeel, et al.
The Lancet. Respiratory Medicine|October 17, 2022
Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trialSantiago Ponce Aix, Tudor Eliade Ciuleanu, Alejandro Navarro, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 8, 2021
Molecular Characterization and Therapeutic Targeting of Colorectal Cancers Harboring Receptor Tyrosine Kinase FusionsHarshabad Singh, Yvonne Y Li, Liam F Spurr, et al.
Cancer Discovery|February 28, 2018
Genomic and Functional Fidelity of Small Cell Lung Cancer Patient-Derived XenograftsBenjamin J Drapkin, Julie George, Camilla L Christensen, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 5, 2015
Assessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung cancerAnthony C Faber, Anna F Farago, Carlotta Costa, et al.
Cancer Discovery|April 11, 2022
Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12CAndreas Weiss, Edwige Lorthiois, Louise Barys, et al.
Cancer Discovery|February 11, 2017
Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)Alexander Drilon, Salvatore Siena, Sai-Hong Ignatius Ou, et al.
The Lancet. Oncology|December 16, 2019
Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trialsRobert C Doebele, Alexander Drilon, Luis Paz-Ares, et al.
Pageof 7

Showing results (51-60 of 63) with videos related to

Sort By:
Pageof 7
JCO Precision Oncology|January 30, 2018
Tracking the Evolution of Resistance to ALK Tyrosine Kinase Inhibitors through Longitudinal Analysis of Circulating Tumor DNAIbiayi Dagogo-Jack, A Rose Brannon, Lorin A Ferris, et al.
The Lancet. Oncology|February 28, 2020
Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trialsDavid S Hong, Steven G DuBois, Shivaani Kummar, et al.
Cancer Discovery|September 27, 2018
Exploiting MCL1 Dependency with Combination MEK + MCL1 Inhibitors Leads to Induction of Apoptosis and Tumor Regression in <i>KRAS</i>-Mutant Non-Small Cell Lung CancerVaruna Nangia, Faria M Siddiqui, Sean Caenepeel, et al.
The Lancet. Respiratory Medicine|October 17, 2022
Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trialSantiago Ponce Aix, Tudor Eliade Ciuleanu, Alejandro Navarro, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 8, 2021
Molecular Characterization and Therapeutic Targeting of Colorectal Cancers Harboring Receptor Tyrosine Kinase FusionsHarshabad Singh, Yvonne Y Li, Liam F Spurr, et al.
Cancer Discovery|February 28, 2018
Genomic and Functional Fidelity of Small Cell Lung Cancer Patient-Derived XenograftsBenjamin J Drapkin, Julie George, Camilla L Christensen, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 5, 2015
Assessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung cancerAnthony C Faber, Anna F Farago, Carlotta Costa, et al.
Cancer Discovery|April 11, 2022
Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12CAndreas Weiss, Edwige Lorthiois, Louise Barys, et al.
Cancer Discovery|February 11, 2017
Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)Alexander Drilon, Salvatore Siena, Sai-Hong Ignatius Ou, et al.
The Lancet. Oncology|December 16, 2019
Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trialsRobert C Doebele, Alexander Drilon, Luis Paz-Ares, et al.
Pageof 7